References

10.1016/b978-0-323-47674-4.00092-x

10.1016/b978-0-323-47674-4.00092-x · 2020 · External reference

Unresolved reference

2023 · External reference

Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study

10.1016/s1470-2045(22)00637-4 · 2022 · External reference

Chronic health conditions and neurocognitive function in aging survivors of childhood cancer: a report from the childhood cancer survivor study

10.1093/jnci/djx224 · 2018 · External reference

Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study

10.1200/jco.2008.16.9607 · 2008 · External reference

Radioligand therapy in cancer management: a global perspective

10.3390/cancers17213412 · 2025 · External reference

Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

10.1016/j.annonc.2020.03.304 · 2020 · External reference

Phase 3 trial of 177 Lu-dotatate for midgut neuroendocrine tumors

10.1056/nejmoa1607427 · 2017 · External reference

Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer

10.1056/nejmoa2107322 · 2021 · External reference

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

10.1016/s0140-6736(24)01653-2 · 2024 · External reference

Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up

10.1016/j.annonc.2025.02.006 · 2025 · External reference

The impact of radioactive iodine on outcomes among pediatric and adolescent thyroid cancer patients: a SEER database analysis

10.3390/cancers17010107 · 2025 · External reference

Theranostics for neuroblastoma: making molecular radiotherapy work better

10.2967/jnumed.124.269121 · 2025 · External reference

The current status and future potential of theranostics to diagnose and treat childhood cancer

10.3389/fonc.2020.578286 · 2020 · External reference

Biochemical diagnosis of catecholamine-producing tumors of childhood: neuroblastoma, pheochromocytoma and paraganglioma

10.3389/fendo.2022.901760 · 2022 · External reference

A narrative review of 35 years of meta-[131I]iodobenzylguanidine therapy in neuroblastoma

10.1016/j.ejcped.2024.100159 · 2024 · External reference

Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy

10.1054/bjoc.2000.1645 · 2001 · External reference

Conditioning regimens megatherapy combining I 131 metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma

10.1038/sj.bmt.1702846 · 2001 · External reference

Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma

10.1200/jco.2004.08.058 · 2004 · External reference

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma

10.1200/jco.2006.09.3484 · 2007 · External reference

Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study

10.1200/jco.2007.15.7628 · 2009 · External reference

I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma

10.1186/1824-7288-38-53 · 2012 · External reference

Dose escalation study of no-carrier-added 131I-Metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial

10.2967/jnumed.111.098624 · 2012 · External reference

Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan

10.1002/pbc.25580;page:string:article/chapter · 2015 · External reference

Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study

10.1186/s13045-017-0477-0 · 2017 · External reference

Phase I/II clinical trial of high-dose [131I] meta-iodobenzylguanidine therapy for high-risk neuroblastoma preceding single myeloablative chemotherapy and haematopoietic stem cell transplantation

10.1007/s00259-021-05630-7 · 2022 · External reference

A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma

10.1016/j.ejca.2013.11.016 · 2014 · External reference

Phase I study of vincristine, irinotecan, and 131I-metaiodobenzylguanidine (131I-MIBG) for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) trial

10.1158/1078-0432.ccr-11-3201 · 2012 · External reference

Phase 1 study of vorinostat as a radiation sensitizer with 131I-metaiodobenzylguanidine (131I-MIBG) for patients with relapsed or refractory neuroblastoma

10.1158/1078-0432.ccr-14-3240 · 2015 · External reference

Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma

10.1200/jco.2002.08.124 · 2002 · External reference

Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study

10.1200/jco.2005.03.6400 · 2006 · External reference

131I-Metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: a new approaches to neuroblastoma therapy (NANT) phase II study

10.1016/j.bbmt.2014.12.008 · 2015 · External reference

Feasibility of busulfan melphalan and stem cell rescue after 131 I-MIBG and topotecan therapy for refractory or relapsed metastatic neuroblastoma: the french experience

10.1097/mph.0000000000001137 · 2018 · External reference

Randomized phase II trial of MIBG versus MIBG, vincristine, and irinotecan versus MIBG and vorinostat for patients with relapsed or refractory neuroblastoma: a report from NANT consortium

10.1200/jco.21.00703 · 2021 · External reference

Phase II study of 131I-metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: results of the french study MIITOP

10.1002/pbc.30615 · 2023 · External reference

Phase I study of 131I-metaiodobenzylguanidine with dinutuximab ± vorinostat for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial

10.1200/jco-24-02612 · 2025 · External reference

A safety and feasibility trial of 131I-MIBG in newly diagnosed high-risk neuroblastoma: a children’s oncology group study

10.1002/pbc.29117 · 2021 · External reference

Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma

10.2967/jnumed.118.217463 · 2019 · External reference

177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma

10.2967/jnumed.110.085100 · 2011 · External reference

Initial experience with gallium-68 DOTA-Octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma

10.1097/mph.0000000000000411 · 2016 · External reference

A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma

10.1007/s00259-020-04741-x · 2020 · External reference

A phase

10.3389/fped.2022.836230 · 2022 · External reference

Peptide receptor radionuclide therapy for metastatic paragangliomas

10.1007/s12032-016-0737-9 · 2016 · External reference

Challenging management of neuroendocrine tumor with hepatic metastasis and carcinoid heart disease in a child

10.1002/pbc.25993 · 2016 · External reference

Peptide receptor radionuclide therapy for treatment of metastatic neuroendocrine tumors in children

10.1002/pbc.29056 · 2021 · External reference

Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: primary analysis of the phase II NETTER-P study

10.1007/s00259-025-07246-7 · 2025 · External reference

[18F]mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study

10.1007/s00259-022-06063-6 · 2023 · External reference

124I-MIBG PET/CT to monitor metastatic disease in children with relapsed neuroblastoma

10.2967/jnumed.120.243139 · 2021 · External reference

124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma

10.5603/nmr.2015.0024 · 2015 · External reference

Safety, biodistribution, and radiation dosimetry of 68Ga-OPS202 in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase I imaging study

10.2967/jnumed.117.199737 · 2018 · External reference

Sensitivity comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study

10.2967/jnumed.117.199760 · 2018 · External reference

A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours

10.1007/s00259-023-06383-1 · 2023 · External reference

Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours

10.1007/s00259-024-06682-1 · 2024 · External reference

Preclinical development of [211At]meta-astatobenzylguanidine ([211At]MABG) as an alpha particle radiopharmaceutical therapy for neuroblastoma

10.1158/1078-0432.ccr-22-0400 · 2022 · External reference

Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma

10.1038/s42003-022-04209-8 · 2022 · External reference

Targeted α-emitter therapy with 212Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-humans dose-escalation clinical trial

10.2967/jnumed.121.263230 · 2022 · External reference

Assessment of [225Ac]Ac-DOTATATE for targeted radioligand therapy in neuroblastoma

10.1016/j.jmir.2026.102231 · 2026 · External reference

Pediatric cancers: insights and novel therapeutic approaches

10.3390/cancers15143537 · 2023 · External reference

High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases

10.1200/jco.2002.20.1.189 · 2002 · External reference

Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma

10.1158/1078-0432.ccr-05-0628 · 2005 · External reference

Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma

10.1002/cncr.24286 · 2009 · External reference

Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma

10.1002/cncr.25518 · 2010 · External reference

86 Re-HEDP in the treatment of patients with inoperable osteosarcoma

2006 · External reference

Alpha particle radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial

10.1158/1078-0432.ccr-18-3964 · 2019 · External reference

B7-H3 is widely expressed in soft tissue sarcomas

10.1186/s12885-024-13061-4 · 2024 · External reference

B7H3-Directed intraperitoneal radioimmunotherapy with radioiodinated omburtamab for desmoplastic small round cell tumor and other peritoneal tumors: results of a phase I study

10.1200/jco.20 · 2020 · External reference

223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy

10.1136/esmoopen-2019-000635 · 2020 · External reference

Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents and young adults

10.1002/pbc.26097 · 2016 · External reference

Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy

10.3389/fonc.2020.01000/full · 2020 · External reference

Recent clinical advances in fibroblast activation protein targeted radioligand therapy for solid tumors

10.3389/fnume.2025.1737443/text · 2025 · External reference

Pediatric brain tumors

10.1016/j.ncl.2018.04.009 · 2018 · External reference

Theranostics in neurooncology: heading toward new horizons

10.2967/jnumed.123.266205 · 2024 · External reference

Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma

10.1007/s11060-009-0038-7 · 2010 · External reference

Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes

10.1007/s11060-019-03139-6 · 2019 · External reference

Central nervous system neuroblastoma metastases pseudoprogression following intraventricular anti-B7H3 radioimmunotherapy

10.1007/s11060-019-03203-1 · 2019 · External reference

Biodistribution and dosimetry of intraventricularly administered 124I-omburtamab in patients with metastatic leptomeningeal tumors

10.2967/jnumed.118.219576 · 2019 · External reference

Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies

10.1186/s13045-022-01383-4 · 2022 · External reference

Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma

10.1007/s11060-022-04235-w · 2023 · External reference

Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial

10.1016/s1470-2045(18)30322-x · 2018 · External reference

Phase 1 dose-escalation trial using convection-enhanced delivery of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma

10.1093/neuonc/noaf039 · 2025 · External reference

Targeted radioimmunotherapy for leptomeningeal cancer using 131I-3F8

10.1002/1096-911x(20001201)35:6<716::aid-mpo51>3.0.co;2-0 · 2000 · External reference

Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8

10.1200/jco.2007.11.1807 · 2007 · External reference

A phase II study of radioimmunotherapy with intraventricular 131I-3F8 for medulloblastoma

10.1002/pbc.26754 · 2018 · External reference

Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma

10.1215/15228517-2008-044 · 2008 · External reference

Results from a phase I study of 4-l-[131I]iodo-phenylalanine ([131I]IPA) with external radiation therapy in patients with recurrent glioblastoma (IPAX-1)

10.1093/noajnl/vdae130 · 2024 · External reference

[18F]FET-PET in children and adolescents with Central nervous system tumors: does it support difficult clinical decision-making?

10.1007/s00259-023-06114-6 · 2023 · External reference

Diagnostic accuracy and clinical impact of [18F]FET PET in childhood CNS tumors

10.1093/neuonc/noab096 · 2021 · External reference

Incidence trends and survival prediction of hepatoblastoma in children: a population-based study

10.1186/s40880-019-0411-7 · 2019 · External reference

Case of advanced hepatocellular carcinoma treated with transarterial radioembolization and subsequent liver transplantation in a 22-month-old

10.1097/mph.0000000000003152 · 2026 · External reference

Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children

10.1002/pbc.27510 · 2019 · External reference

Yttrium-90 transarterial radioembolization as a bridging therapy to liver transplant in a toddler with pretreatment extent (PRETEXT) IV hepatoblastoma

10.7759/cureus.87107 · 2025 · External reference

Transarterial radioembolization treatment as a bridge to surgical resection in pediatric hepatocellular carcinoma

10.1097/mph.0000000000002089 · 2021 · External reference

Trans-arterial radioembolization with yttrium-90 of unresectable and systemic chemotherapy resistant hepatoblastoma in three toddlers

10.1007/s00270-021-03026-6 · 2022 · External reference

Successful use of transarterial radioembolization with yttrium-90 (TARE-Y90) in two children with hepatoblastoma

10.1002/pbc.28421 · 2020 · External reference